Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBT-877 Single Dose in Healthy Japanese Men
NCT04138849Phase 1Completed
- Sponsor
- Bridge Biotherapeutics
- Start
- Oct 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of LCB17-0877 in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Bridge Biotherapeutics. Primary endpoint: Adverse events (AEs). Started Oct 2019; status: completed.
02
Drugs
LCB17-0877
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04138849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04138849.